Myriad Genetics, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own3.60% Shs Outstand80.40M Perf Week6.82%
Market Cap1.72B Forward P/E130.12 EPS next Y0.16 Insider Trans-0.22% Shs Float79.02M Perf Month-2.48%
Income-17.60M PEG- EPS next Q-0.01 Inst Own- Short Float4.97% Perf Quarter6.22%
Sales672.30M P/S2.55 EPS this Y68.10% Inst Trans0.89% Short Ratio7.62 Perf Half Y-13.61%
Book/sh11.78 P/B1.77 EPS next Y800.00% ROA-1.40% Target Price25.00 Perf Year-33.97%
Cash/sh2.49 P/C8.37 EPS next 5Y-8.20% ROE-1.80% 52W Range16.02 - 33.09 Perf YTD-24.57%
Dividend- P/FCF- EPS past 5Y-26.50% ROI-1.80% 52W High-37.08% Beta1.73
Dividend %- Quick Ratio2.90 Sales past 5Y-1.10% Gross Margin71.50% 52W Low29.96% ATR1.00
Employees2400 Current Ratio3.10 Sales Q/Q-5.30% Oper. Margin-6.60% RSI (14)48.95 Volatility4.43% 4.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-188.10% Profit Margin-2.60% Rel Volume0.90 Prev Close20.61
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume514.96K Price20.82
Recom3.50 SMA201.07% SMA50-10.79% SMA200-10.49% Volume465,699 Change1.02%
Oct-15-21Resumed Cowen Market Perform $33
Jun-15-21Initiated Raymond James Mkt Perform
Jun-03-21Initiated Goldman Sell $25
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Sep-28-22 09:00AM
Sep-26-22 03:55PM
Aug-31-22 08:00AM
Aug-29-22 12:33PM
10:23AM Loading…
Aug-26-22 01:15PM
Aug-25-22 04:05PM
Aug-21-22 08:20AM
Aug-16-22 01:05AM
Aug-05-22 12:01PM
Aug-04-22 09:15AM
Jul-28-22 04:05PM
Jul-19-22 05:07PM
08:26AM Loading…
Jul-13-22 08:26AM
Jul-12-22 04:12PM
Jul-11-22 10:33AM
Jun-28-22 04:05PM
Jun-27-22 09:02AM
Jun-23-22 04:05PM
Jun-09-22 05:30PM
May-26-22 06:30PM
May-06-22 11:01AM
May-05-22 09:45AM
May-04-22 06:15PM
May-03-22 04:15PM
04:05PM Loading…
Apr-28-22 04:05PM
Apr-26-22 07:05AM
Mar-22-22 09:42AM
Mar-17-22 12:24PM
Mar-14-22 10:24AM
Mar-11-22 07:05PM
Mar-08-22 07:22AM
Mar-02-22 04:30PM
Feb-27-22 07:12AM
Feb-25-22 08:50AM
Feb-24-22 10:25AM
Feb-23-22 04:30PM
Feb-17-22 05:15PM
Feb-16-22 07:05AM
Feb-15-22 03:01PM
Feb-14-22 07:05AM
Feb-01-22 10:39AM
Jan-05-22 07:05AM
Jan-04-22 04:47PM
Dec-15-21 10:47AM
Dec-14-21 04:05PM
Nov-23-21 07:05AM
Nov-22-21 07:05AM
Nov-03-21 09:36AM
Nov-02-21 08:01PM
Oct-27-21 05:05PM
Oct-18-21 07:05AM
Oct-11-21 12:01AM
Oct-04-21 05:53PM
Sep-29-21 07:00PM
Sep-13-21 04:05PM
Sep-08-21 04:05PM
Sep-07-21 09:15AM
Aug-24-21 11:44AM
Aug-04-21 08:41AM
Aug-03-21 10:01PM
Aug-02-21 07:05AM
Jul-28-21 04:05PM
Jul-21-21 04:05PM
Jul-02-21 07:14AM
Jul-01-21 04:05PM
Jun-16-21 04:05PM
Jun-04-21 07:05AM
Jun-02-21 11:30AM
Jun-01-21 07:05AM
May-31-21 07:22AM
May-27-21 11:01AM
May-24-21 07:05AM
May-20-21 07:05AM
May-19-21 05:55PM
May-05-21 04:05PM
May-04-21 08:07AM
May-03-21 06:35PM
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPIEGELMAN DANIEL KDirectorJun 06Sale19.256,424123,67333,980Jun 06 07:20 PM
Hart Jayne B.Chief People OfficerFeb 28Option Exercise23.9810,500251,790172,878Mar 01 04:55 PM
Hart Jayne B.Chief People OfficerFeb 28Sale25.0010,500262,500165,878Mar 01 04:55 PM